Exploring the usability of a point-of-care hearing screening by oncology registered nurses with adult cancer patients during Cisplatin chemotherapy - A convergent mixed methods study

Ototoxicity, defined as hearing loss and tinnitus, affects more than 50% of cancer survivors treated with Cisplatin chemotherapy. Despite national recommendations for routine symptom monitoring, hearing screenings remain underutilized in oncology. Point-of-care (POC) technologies offer a promising solution to enhance ototoxicity detection during chemotherapy....

Point-of-care hearing screening by oncology nurses appears usable in Cisplatin chemotherapy settings, but adoption into audiology practice depends on validation of screening accuracy and integration with referral pathways — current evidence is insufficient to mandate a practice change.

Cisplatin-induced ototoxicity is common yet monitoring is inconsistent; empowering bedside nurses to screen could dramatically increase early detection rates without requiring direct audiologist presence at every chemotherapy visit.

1. 01Convergent mixed-methods design combined quantitative usability metrics with qualitative nurse feedback.
2. 02Oncology nurses, not audiologists, administered the point-of-care hearing screen during Cisplatin infusions.
3. 03Tool targets early detection of ototoxicity (medication-caused hearing damage) in adult cancer patients.
4. 04Nurse-administered screening could expand monitoring access in resource-limited oncology settings.
5. 05Diagnostic accuracy of the screening tool against gold-standard audiology testing is not the primary focus here.

PMID

42497611

DOI

10.1016/j.ejon.2026.103284.

Journal

European Journal of Oncology Nursing

Publication type

research_article

Evidence level

2b

Population

Adult cancer patients undergoing Cisplatin chemotherapy, screened by oncology registered nurses

Intervention

Point-of-care hearing screening tool administered by oncology nurses